Aside from Panx1 targeting peptides which have yet to reach clinical success, evidence suggests that Probenecid and Spironolactone are the most selective of the pharmacologic pannexin inhibitors (Koval et al. 2023), and their therapeutic role in cardiovascular disease is a topic of ongoing research. This evidence concerns the gene PANX1 and cardiovascular disorder.